Free Trial

Gain Therapeutics (GANX) Competitors

Gain Therapeutics logo
$1.58 -0.03 (-1.55%)
Closing price 04:00 PM Eastern
Extended Trading
$1.57 -0.01 (-0.95%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GANX vs. CTMX, DRUG, SOPH, FDMT, YMAB, ENGN, EPRX, GNFT, OGI, and NLTX

Should you be buying Gain Therapeutics stock or one of its competitors? The main competitors of Gain Therapeutics include CytomX Therapeutics (CTMX), Bright Minds Biosciences (DRUG), SOPHiA GENETICS (SOPH), 4D Molecular Therapeutics (FDMT), Y-mAbs Therapeutics (YMAB), enGene (ENGN), Eupraxia Pharmaceuticals (EPRX), GENFIT (GNFT), Organigram Global (OGI), and Neoleukin Therapeutics (NLTX). These companies are all part of the "pharmaceutical products" industry.

Gain Therapeutics vs. Its Competitors

Gain Therapeutics (NASDAQ:GANX) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations.

In the previous week, Gain Therapeutics had 4 more articles in the media than CytomX Therapeutics. MarketBeat recorded 4 mentions for Gain Therapeutics and 0 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 1.31 beat Gain Therapeutics' score of 0.61 indicating that CytomX Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Gain Therapeutics Positive
CytomX Therapeutics Positive

CytomX Therapeutics has higher revenue and earnings than Gain Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gain Therapeutics$50K953.22-$20.41M-$0.86-1.84
CytomX Therapeutics$138.10M1.39$31.87M$0.484.96

Gain Therapeutics presently has a consensus price target of $8.20, suggesting a potential upside of 417.35%. CytomX Therapeutics has a consensus price target of $5.33, suggesting a potential upside of 124.09%. Given Gain Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Gain Therapeutics is more favorable than CytomX Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gain Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.17
CytomX Therapeutics
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

CytomX Therapeutics has a net margin of 28.22% compared to Gain Therapeutics' net margin of 0.00%. Gain Therapeutics' return on equity of -247.55% beat CytomX Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Gain TherapeuticsN/A -247.55% -146.06%
CytomX Therapeutics 28.22%-553.71%32.21%

12.0% of Gain Therapeutics shares are held by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are held by institutional investors. 7.2% of Gain Therapeutics shares are held by insiders. Comparatively, 6.6% of CytomX Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Gain Therapeutics has a beta of 0.12, indicating that its stock price is 88% less volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 2.05, indicating that its stock price is 105% more volatile than the S&P 500.

Summary

CytomX Therapeutics beats Gain Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Gain Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GANX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GANX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GANX vs. The Competition

MetricGain TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$48.41M$2.46B$5.54B$9.41B
Dividend YieldN/A1.80%3.75%4.03%
P/E Ratio-1.844.4521.0120.09
Price / Sales953.22709.89433.8199.01
Price / CashN/A164.7736.1658.27
Price / Book5.665.008.125.65
Net Income-$20.41M$30.99M$3.25B$257.91M
7 Day Performance-8.38%1.69%0.97%2.09%
1 Month Performance-11.45%9.20%7.36%11.13%
1 Year Performance29.92%-1.25%31.31%18.40%

Gain Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GANX
Gain Therapeutics
2.344 of 5 stars
$1.59
-1.6%
$8.20
+417.4%
+26.8%$48.41M$50K-1.8420
CTMX
CytomX Therapeutics
4.1776 of 5 stars
$2.37
-5.2%
$5.33
+125.0%
+65.3%$201.55M$138.10M4.94170Positive News
DRUG
Bright Minds Biosciences
2.4488 of 5 stars
$27.33
-3.7%
$83.25
+204.6%
+2,102.5%$199.84MN/A-75.91N/APositive News
SOPH
SOPHiA GENETICS
2.7866 of 5 stars
$3.25
+8.7%
$7.00
+115.4%
-20.4%$199.39M$65.17M-3.25520High Trading Volume
FDMT
4D Molecular Therapeutics
2.2164 of 5 stars
$3.95
-6.8%
$29.56
+648.2%
-76.0%$196.42M$40K-1.24120
YMAB
Y-mAbs Therapeutics
4.1825 of 5 stars
$4.22
-1.9%
$15.60
+269.7%
-65.7%$194.72M$87.68M-6.59150Positive News
ENGN
enGene
2.876 of 5 stars
$3.81
+0.3%
$23.29
+511.2%
-59.4%$194.20MN/A-2.3131
EPRX
Eupraxia Pharmaceuticals
2.288 of 5 stars
$5.54
+2.8%
$11.00
+98.6%
+108.1%$193.81MN/A-7.2929
GNFT
GENFIT
2.4738 of 5 stars
$3.69
-4.8%
$13.00
+252.7%
-17.0%$193.49M$76.77M0.00120Positive News
Upcoming Earnings
Gap Up
OGI
Organigram Global
0.8702 of 5 stars
$1.39
-2.8%
N/A-13.6%$191.53M$117.47M13.90860
NLTX
Neoleukin Therapeutics
N/A$20.09
+1.7%
N/A-49.2%$188.81MN/A-6.4690

Related Companies and Tools


This page (NASDAQ:GANX) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners